ADVERTISEMENT

Ranbaxy Volini Duo

Source: 
Ranbaxy
Ranbaxy logo

Pharmaceuticals major Ranbaxy Laboratories Ltd today said it had launched "Volini Duo", India's first approved two-in-one pain killer, for the first time in India.

The bi-layered acetaminophen tablet, introduced by the over-the-counter (OTC) business division of the company, Ranbaxy Global Consumer Healthcare (RGCH), has been specially formulated to give dual pain relief, a press release from the company said.

"Ranbaxy remains committed to developing and offering quality, safe, efficacious and innovative solutions to consumers. The introduction of ‘Volini Duo’ is a move in this direction," Mr. Brijesh Kapil, Vice President, RGCH, said.

According to the release, Volini Duo has been developed by scientists at Ranbaxy’s state-of-the-art R&D centre in Gurgaon, using advanced Matrix technology, which enables the regulated release of the medicine in the gastrointestinal tract.

"It is specifically effective for back & joint pains, which are primarily chronic in nature. Unlike regular pain killers which give relief for upto four hours, Volini Duo with its unique matrix formulation, provides relief for double the duration of around 8 hours. The product has a high safety profile making it ideal for mass use," the release said.

According to it, Volini Duo tablet marks the entry of Ranbaxy in the OTC oral pain reliever category.

The OTC oral analgesics market in India is estimated to be Rs 700 crore and is growing annually at a rate of 10.5%.

"Globally, acetaminophen happens to be the highest selling molecule in the OTC pain reliever category. Due to today’s fast paced lifestyle and lack of exercise, there is an increasing incidence of back pain, joint pain, body aches and muscular sprains," it said.

Ranbaxy Global Consumer Healthcare (RGCH) was established in October 2002 with an objective to promote OTC healthcare brands to consumers. The major brands from RGCH include Revital, Volini (pain relieving Gel & Spray), Chericof (Cough Syrup), Pepfiz (Digestive).

NNN

Contact Details: 

Ranbaxy

© Copyright 2012 NetIndian. All rights reserved. Republication or redistribution of NetIndian content, including by framing or similar means, is expressly prohibited without the prior written consent of NetIndian Media Corporation. Write to info[AT]netindian[DOT]in for permission to use content. Read detailed Terms of Use.